FibroTouch检测肝脏硬度值联合门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化的临床价值

肝脏 ›› 2024, Vol. 29 ›› Issue (10): 1230-1234.

FibroTouch检测肝脏硬度值联合门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化的临床价值

党苗苗, 杜苗苗, 高艳梅

727000 陕西铜川市人民医院超声医学科(党苗苗);710077 陕西西安医学院第二附属医院超声医学科(杜苗苗);727031 陕西北京中医药大学孙思邈医院超声医学科(高艳梅)

收稿日期:2024-07-15 出版日期:2024-10-31 发布日期:2024-12-02
通讯作者: 高艳梅,Email:1227097150@qq.com
基金资助:
陕西省重点研发计划项目(2020SF-177)

Clinical value of liver stiffness value detected by FibroTouch combined with portal vein hemodynamics in evaluating liver fibrosis in patients with chronic hepatitis B

DANG Miao-miao¹, DU Miao-miao², GAO Yan-mei³

1. Department of Ultrasound Medicine, Tongchuan People's Hospital, Shaanxi 727000, China;
2. Department of Ultrasound Medicine, the Second Affiliated Hospital of Xi'an Medical University, Shaanxi 710077;
3. Department of Ultrasound Medicine, Sun Simmiao Hospital, Beijing University of Chinese Medicine, Tongchuan 727031, China

Received:2024-07-15 Online:2024-10-31 Published:2024-12-02
Contact: GAO Yan-mei,Email:1227097150@qq.com

摘要/Abstract

摘要： 目的探讨肝脏硬度值(LSM)联合多普勒超声检测门静脉血流动力学指标对慢性乙型肝炎(CHB)患者肝纤维化的评估价值。方法 2020年8月—2023年7月我院收治的CHB患者99例,均进行肝活检、瞬时弹性成像技术和多普勒超声检查,记录其肝纤维化情况、LSM、门静脉主干内径(PVD)、静息状态下门静脉最大流速(Vmax)及平均流速(Vmean),根据患者Metavir纤维化评分系统将其分为无肝纤维化组(F0期)、轻度肝纤维化组(F1~F2期)和显著肝纤维组(≥F3期),对比三组LSM、PVD、Vmax及Vmean,采用Spearman相关性分析对LSM、PVD、Vmax及Vmean与Metavir评分的相关性进行分析,受试者工作曲线(ROC)分析LSM、PVD、Vmax及Vmean对CHB患者肝纤维化的评估价值。结果病理活检显示,本次99例患者中F0期16例,F1期30例,F2期24例,F3期20例,F4期9例。LSM、PVD:显著肝纤维化组[(13.67±1.95)kPa、(13.35±1.32)mm]>轻度肝纤维化组[(6.81±0.97)kPa、(11.77±1.15)mm]>无肝纤维化组[(5.12±0.84)kPa、(10.84±1.04)mm](P<0.05),Vmax、Vmean:显著肝纤维化组[(29.04±2.11)cm/s、(24.58±1.93)cm/s]<轻度肝纤维化组[(33.26±2.04)cm/s、(27.10±1.86)cm/s]<无肝纤维化组[(37.18±1.67)cm/s、(32.67±1.75)cm/s](P<0.05)。CHB患者LSM、PVD与Metavir评分均呈显著正相关性(r=0.649,r=0.477,P<0.05),Vmax、Vmean与Metavir评分均呈显著负相关性(r=-0.561,r=-0.538,P<0.05)。CHB患者LSM、PVD、Vmax、Vmean及其联合检测评估CHB患者显著肝纤维化的AUC值分别为0.938、0.886、0.800、0.867、0.983,敏感度分别为82.76%、89.66%、82.76%、79.31%、96.55%,特异度分别为91.43%、80.00%、64.29%、77.14%、90.00%,联合检测对CHB患者显著肝纤维化的评估效能优于各指标单独检测(P<0.05)。结论 LSM及门静脉血流动力学指标与CHB患者肝纤维化有关,LSM联合多普勒超声检测门静脉血流动力学指标检测对CHB患者肝纤维化具有良好的评估效能。

关键词: 慢性乙型肝炎, 多普勒超声, 门静脉血流动力学, 肝脏硬度值, 肝纤维化

Abstract: Objective To explore the evaluation value of liver stiffness value (LSM) combined with the portal vein hemodynamic indicators detected by Doppler ultrasound for liver fibrosis in patients with chronic hepatitis B (CHB). Methods Between August 2020 and July 2023, 99 CHB patients admitted to our hospital underwent liver biopsy, instantaneous elastography, and Doppler ultrasound examination. Their liver fibrosis status, LSM, portal vein main diameter (PVD), resting portal vein maximum flow velocity (Vmax), and mean flow velocity (Vmean) were recorded. According to the Metavir fibrosis scoring system of patients, they were divided into three groups: without liver fibrosis (F0 stage), mild liver fibrosis group (F1-F2 stage) and significant liver fibrosis group (≥ F3 stage). The LSM, PVD, Vmax, and Vmean of the three groups were compared. Spearman correlation analysis was used to analyze the correlation among the LSM, PVD, Vmax, Vmean and Metavir score. Receiver operating curve (ROC) analysis was used to evaluate the value of LSM, PVD, Vmax, and Vmean in evaluating liver fibrosis in CHB patients. Results Pathological biopsy showed that among the 99 patients, there were 16 cases in F0 stage, 30 cases in F1 stage, 24 cases in F2 stage, 20 cases in F3 stage, and 9 cases in F4 stage. LSM and PVD: significant hepatic fibrosis group [(13.67±1.95) kPa, (13.35±1.32) mm] > mild hepatic fibrosis group [(6.81±0.97) kPa, (11.77±1.15) mm] > no hepatic fibrosis group [(5.12±0.84) kPa、(10.84±1.04) mm]. Vmax, Vmean: significant hepatic fibrosis group [(29.04±2.11) cm/s, (24.58±1.93) cm/s] < mild hepatic fibrosis group [(33.26±2.04) cm/s, (27.10±1.86) cm/s]. LSM, PVD and Metavir score in CHB patients were significantly positively correlated (r=0.649, r=0.477, P<0.05), while Vmax and Vmean were significantly negatively correlated with Metavir score (r=-0.561, r=-0.538, P<0.05). The area under the curve (AUC) of LSM, PVD, Vmax, Vmean, and their combined detection for evaluating significant liver fibrosis in CHB patients were 0.938, 0.886, 0.800, 0.867, and 0.983, respectively, with sensitivities of 82.76%, 89.66%, 82.76%, 79.31%, and 96.55%, and specificity of 91.43%, 80.00%, 64.29%, 77.14%, and 90.00%. The combined detection had a better evaluation efficacy for significant liver fibrosis in CHB patients than the individual detection of each indicator (P<0.05). Conclusion LSM and portal vein hemodynamic indicators are related to the liver fibrosis in CHB patients. The combination of LSM and Doppler ultrasound detection of portal vein hemodynamic indicators has a good evaluation efficacy for liver fibrosis in CHB patients.

Key words: Chronic hepatitis B, Doppler ultrasound, Portal venous hemodynamics, Liver hardness value, Hepatic fibrosis

党苗苗, 杜苗苗, 高艳梅. FibroTouch检测肝脏硬度值联合门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化的临床价值[J]. 肝脏, 2024, 29(10): 1230-1234.

DANG Miao-miao, DU Miao-miao, GAO Yan-mei. Clinical value of liver stiffness value detected by FibroTouch combined with portal vein hemodynamics in evaluating liver fibrosis in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2024, 29(10): 1230-1234.

/ 推荐

参考文献

[1] Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol & Ther,2021,54(9):1100-1109.
[2] Hsu Y C, Tseng C H, Su T H, et al. Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities[J]. Gut,2022,71(6):1238-1240.
[3] 赵鸿. 丙氨酸转氨酶正常慢性乙型肝炎病毒感染者启动抗病毒治疗的恰当指标[J]. 中华肝脏病杂志,2021,29(9):883-884.
[4] Mak LY, Lee CH, Cheung KS, et al. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue[J]. Liver Int,2019,39(7):1217-1225.
[5] 周宇辰, 胡承光, 袁国盛, 等. 抗病毒联合抗肝纤维化治疗慢性乙型肝炎肝纤维化降低肝细胞癌发生:144周的前瞻性队列研究[J]. 南方医科大学学报,2019,39(6):633-640.
[6] Wang Q, Liu H F, Zhu Z H, et al. Feasibility of T1 mapping with histogram analysis for the diagnosis and staging of liver fibrosis: Preclinical results[J]. Magn Reson Imaging,2021,76:79-86.
[7] 王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志,2019, 35(12):2648-2669.[1]
[8] Trusty P M, Wei Z A, Rychik J, et al. Cardiac Magnetic Resonance-Derived Metrics Are Predictive of Liver Fibrosis in Fontan Patients[J]. Ann Thorac Surg,2019,109(6):1904-1911.
[9] Lagha I B, Jaber K, Rabhi F, et al. Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis[J]. Br J Dermatol,2019,181(6):1306-1308.
[10] 周克丽, 吕晓丽, 周洋, 等. 应用肝脏硬度检测联合多普勒超声检测门静脉血流动力学指标评估慢性乙型肝炎患者肝纤维化效能研究[J]. 实用肝脏病杂志,2023,26(4):480-483.
[11] Gaballa D, Bezinover D, Kadry Z, et al. Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index[J]. Liver Transpl,2019,25(12):1747-1755.
[12] Chatelin S, Pop R, Céline Giraudeau, et al. Influence of portal vein occlusion on portal flow and liver elasticity in an animal model[J]. NMR Biomed,2021,34(6):e4498.
[13] Kohno S, Isoda H, Ono A, et al. Portal Vein Embolization: Radiological Findings Predicting Future Liver Remnant Hypertrophy[J]. AJR Am J Roentgenol,2019,214(3):687-693.
[14] Hidetoshi G, Masahiro K, Motofumi T, et al. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma[J]. Surgery,2018,164(5):1014-1022.
[15] 董丙田, 黄枢, 常建东, 等. 声触诊弹性成像与4项血清纤维化指标评估慢性乙型肝炎肝纤维化的效能比较[J]. 中华肝脏病杂志,2020,28(3):269-272.
[16] 丁荣蓉, 陆伟, 王雁冰, 等. 采用瞬时弹性成像技术和血清标志物预测丙氨酸转氨酶轻度升高的慢性乙型肝炎患者肝纤维化程度[J]. 中华传染病杂志,2019,37(2):72-76.
[17] Xing Y, Tian Z, Jiang Y, et al. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis[J]. Ann Med,2022,54(1):302-309.
[18] Boyer-Diaz Z, Aristu-Zabalza P, María Andrés-Rozas, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease[J]. J Hepatol,2021,74(5):1188-1199.